190 related articles for article (PubMed ID: 33901770)
1. Parallel discovery of selective and dual inhibitors of tryptophan dioxygenases IDO1 and TDO2 with a newly-modified enzymatic assay.
Capochiani de Iudicibus R; Tomek P; Palmer BD; Tijono SM; Flanagan JU; Ching LM
Bioorg Med Chem; 2021 Jun; 39():116160. PubMed ID: 33901770
[TBL] [Abstract][Full Text] [Related]
2. Discovery and Characterisation of Dual Inhibitors of Tryptophan 2,3-Dioxygenase (TDO2) and Indoleamine 2,3-Dioxygenase 1 (IDO1) Using Virtual Screening.
Sari S; Tomek P; Leung E; Reynisson J
Molecules; 2019 Nov; 24(23):. PubMed ID: 31795096
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of Novel Inhibitors of Tryptophan Dioxygenases for Enzyme and Species Selectivity Using Engineered Tumour Cell Lines Expressing Either Murine or Human IDO1 or TDO2.
Tijono SM; Palmer BD; Tomek P; Flanagan JU; Henare K; Gamage S; Braun L; Ching LM
Pharmaceuticals (Basel); 2022 Aug; 15(9):. PubMed ID: 36145311
[TBL] [Abstract][Full Text] [Related]
4. Discovery and characterization of natural products as novel indoleamine 2,3-dioxygenase 1 inhibitors through high-throughput screening.
Guo W; Yao S; Sun P; Yang TB; Tang CP; Zheng MY; Ye Y; Meng LH
Acta Pharmacol Sin; 2020 Mar; 41(3):423-431. PubMed ID: 31197246
[TBL] [Abstract][Full Text] [Related]
5. Identification of selective inhibitors of indoleamine 2,3-dioxygenase 2.
Bakmiwewa SM; Fatokun AA; Tran A; Payne RJ; Hunt NH; Ball HJ
Bioorg Med Chem Lett; 2012 Dec; 22(24):7641-6. PubMed ID: 23122865
[TBL] [Abstract][Full Text] [Related]
6. Characterization of indoleamine-2,3-dioxygenase 1, tryptophan-2,3-dioxygenase, and Ido1/Tdo2 knockout mice.
Aslamkhan AG; Xu Q; Loughlin A; Vu H; Pacchione S; Bhatt B; Garfinkel I; Styring TG; LaFranco-Scheuch L; Pearson K; Reynolds S; Li N; Zhou H; Miller JR; Solban N; Bass A; Glaab WE
Toxicol Appl Pharmacol; 2020 Nov; 406():115216. PubMed ID: 32871117
[TBL] [Abstract][Full Text] [Related]
7. Discovery and evaluation of inhibitors to the immunosuppressive enzyme indoleamine 2,3-dioxygenase 1 (IDO1): Probing the active site-inhibitor interactions.
Tomek P; Palmer BD; Flanagan JU; Sun C; Raven EL; Ching LM
Eur J Med Chem; 2017 Jan; 126():983-996. PubMed ID: 28011425
[TBL] [Abstract][Full Text] [Related]
8. Preparation and evaluation of L- and D-5-[
Tang T; Gill HS; Ogasawara A; Tinianow JN; Vanderbilt AN; Williams SP; Hatzivassiliou G; White S; Sandoval W; DeMent K; Wong M; Marik J
Nucl Med Biol; 2017 Aug; 51():10-17. PubMed ID: 28511073
[TBL] [Abstract][Full Text] [Related]
9. In silico discovery and therapeutic potential of IDO1 and TDO2 inhibitors.
Jernigan FE; Sun L
Future Med Chem; 2017 Aug; 9(12):1309-1311. PubMed ID: 28771034
[No Abstract] [Full Text] [Related]
10. Discovery of novel IDO1/TDO2 dual inhibitors: a consensus Virtual screening approach with molecular dynamics simulations, and binding free energy analysis.
Hanif N; Sari S
J Biomol Struct Dyn; 2024 Mar; ():1-17. PubMed ID: 38498355
[TBL] [Abstract][Full Text] [Related]
11. Challenges in the Discovery of Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors.
Röhrig UF; Majjigapu SR; Vogel P; Zoete V; Michielin O
J Med Chem; 2015 Dec; 58(24):9421-37. PubMed ID: 25970480
[TBL] [Abstract][Full Text] [Related]
12. Discovery and characterisation of hydrazines as inhibitors of the immune suppressive enzyme, indoleamine 2,3-dioxygenase 1 (IDO1).
Fung SP; Wang H; Tomek P; Squire CJ; Flanagan JU; Palmer BD; Bridewell DJ; Tijono SM; Jamie JF; Ching LM
Bioorg Med Chem; 2013 Dec; 21(24):7595-603. PubMed ID: 24262887
[TBL] [Abstract][Full Text] [Related]
13. A highly efficient modality to block the degradation of tryptophan for cancer immunotherapy: locked nucleic acid-modified antisense oligonucleotides to inhibit human indoleamine 2,3-dioxygenase 1/tryptophan 2,3-dioxygenase expression.
Klar R; Michel S; Schell M; Hinterwimmer L; Zippelius A; Jaschinski F
Cancer Immunol Immunother; 2020 Jan; 69(1):57-67. PubMed ID: 31802183
[TBL] [Abstract][Full Text] [Related]
14. Discovery of novel IDO1 inhibitors via structure-based virtual screening and biological assays.
Ge H; Mao L; Zhao J; Wang Y; Shi D; Yang X; Wang X; Liu H; Yao X
J Comput Aided Mol Des; 2021 May; 35(5):679-694. PubMed ID: 33905074
[TBL] [Abstract][Full Text] [Related]
15. Dual inhibition of IDO1/TDO2 enhances anti-tumor immunity in platinum-resistant non-small cell lung cancer.
Wu C; Spector SA; Theodoropoulos G; Nguyen DJM; Kim EY; Garcia A; Savaraj N; Lim DC; Paul A; Feun LG; Bickerdike M; Wangpaichitr M
Cancer Metab; 2023 May; 11(1):7. PubMed ID: 37226257
[TBL] [Abstract][Full Text] [Related]
16. A Novel High Throughput Virtual Screening Protocol to Discover New Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors.
Xu H; Song Y; Yang Q
Chem Pharm Bull (Tokyo); 2017; 65(8):714-717. PubMed ID: 28768924
[TBL] [Abstract][Full Text] [Related]
17. Discovery and structure-activity relationship studies of 1-aryl-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione derivatives as potent dual inhibitors of indoleamine 2,3-dioxygenase 1 (IDO1) and trytophan 2,3-dioxygenase (TDO).
Pan S; Zhou Y; Wang Q; Wang Y; Tian C; Wang T; Huang L; Nan J; Li L; Yang S
Eur J Med Chem; 2020 Dec; 207():112703. PubMed ID: 32871341
[TBL] [Abstract][Full Text] [Related]
18. 4,6-Substituted-1H-Indazoles as potent IDO1/TDO dual inhibitors.
Yang L; Chen Y; He J; Njoya EM; Chen J; Liu S; Xie C; Huang W; Wang F; Wang Z; Li Y; Qian S
Bioorg Med Chem; 2019 Mar; 27(6):1087-1098. PubMed ID: 30773421
[TBL] [Abstract][Full Text] [Related]
19. Tryptophan catabolism is dysregulated in leiomyomas.
Chuang TD; Quintanilla D; Boos D; Khorram O
Fertil Steril; 2021 Oct; 116(4):1160-1171. PubMed ID: 34116832
[TBL] [Abstract][Full Text] [Related]
20. Targeting the IDO1/TDO2-KYN-AhR Pathway for Cancer Immunotherapy - Challenges and Opportunities.
Cheong JE; Sun L
Trends Pharmacol Sci; 2018 Mar; 39(3):307-325. PubMed ID: 29254698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
